Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Calithera Biosciences, Inc. (CALA) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/25/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
01/09/2023 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution"
11/14/2022 8-K Quarterly results
09/29/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
06/14/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/23/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
04/12/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
03/31/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, by and among Calithera Biosciences, Inc., SVB Securities LLC and H.C. Wainwright & Co., LLC",
"Form of Short-Term Common Stock Warrant",
"Form of Long-Term Common Stock Warrant",
"Form of Warrant Agency Agreement by and between Calithera Biosciences, Inc. and American Stock Transfer & Trust Company, LLC",
"Opinion of Cooley LLP"
01/28/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/05/2022 8-K Investor presentation
Docs: "Calithera Biosciences, Inc. corporate presentation, dated January 2022"
12/30/2021 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
11/09/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Calithera Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights"
11/05/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial",
"Calithera Biosciences Promotes Emil T. Kuriakose, MD, to Chief Medical Officer"
10/19/2021 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sales of Equity Secur...
Docs: "Calithera Biosciences, Inc. Certificate of Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock",
"Preferred Stock Purchase Agreement, by and between Calithera Biosciences, Inc. and Millennium Pharmaceuticals, Inc",
"— TORC 1/2 inhibitor sapanisertib and SYK inhibitor mivavotinib strengthen Company's precision oncology pipeline — — Calithera will initiate Phase 2 clinical trials of sapanisertib and mivavotinib in 2022",
"Investor Presentation",
"Risk Factors"
09/16/2021 8-K Quarterly results
08/05/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Calithera Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights — Cash and Cash Equivalents Totaled $92.2 million as of June 30, 2021 — — Conference Call and Webcast Scheduled for 2:00 p.m. PT on August 5, 2021— SOUTH SAN FRANCISCO, Calif., August 5, 2021 - Calithera Biosciences, Inc. , a fully-integrated clinical stage biotechnology company focused on discovering and developing novel, small molecule drugs for the treatment of cancer and other life-threatening diseases, announced today its financial results for the second quarter ended June 30, 2021. “In the second quarter, we announced a license agreement with Antengene for the development of CB-708, a potential first-in-class oral small molecule CD73 inhibitor developed internally via our drug discovery engine,”..."
06/14/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
03/16/2021 8-K Quarterly results
01/26/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "2014 Equity Incentive Plan, as amended"
01/04/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Calithera Biosciences Reports Third Quarter 2020 Financial Results and Recent Highlights —Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on November 5, 2020— SOUTH SAN FRANCISCO, Calif., November 5, 2020 - Calithera Biosciences, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel, small-molecule drugs for the treatment of cancer and other life-threatening diseases, announced today its financial results for the third quarter ended September 30, 2020. “To date, 2020 has been a significant year for Calithera as we've made remarkable progress to advance our clinical development efforts across our pipeline and work toward reporting our first pivotal trial results with our lead candidate glutaminase inhibitor telaglenas..."
09/03/2020 8-K Other Events  Interactive Data
08/10/2020 8-K Quarterly results
07/14/2020 8-K Quarterly results
06/12/2020 8-K Submission of Matters to a Vote of Security Holders
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : June 9, 2020 Calithera Biosciences, Inc. Delaware 001-36644 27-2366329 343 Oyster Point Blvd. Suite 200 South San Francisco, California 94080 Registrant's telephone number, including area code: 870-1000 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) &#..."
05/07/2020 8-K Quarterly results
04/16/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 of The Securities Exchange Act of 1934 Date of Report : April 15, 2020 Calithera Biosciences, Inc. Delaware 001-36644 27-2366329 343 Oyster Point Blvd., Suite 200 South San Francisco, California 94080 Registrant's telephone number, including area code: 870-1000 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ...",
"Underwriting Agreement",
"Opinion of Cooley LLP"
03/11/2020 8-K Quarterly results
01/16/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : January 10, 2020 Calithera Biosciences, Inc. Delaware 001-36644 27-2366329 343 Oyster Point Blvd., Suite 200 South San Francisco, California 94080 Registrant's telephone number, including area code: 870-1000 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Ac..."
01/13/2020 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : January 13, 2020 Calithera Biosciences, Inc. Delaware 001-36644 27-2366329 343 Oyster Point Blvd., Suite 200 South San Francisco, California 94080 Registrant's telephone number, including area code: 870-1000 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Ac...",
"Calithera Biosciences Provides Overview of 2020 Corporate Milestones and Financial Guidance SOUTH SAN FRANCISCO, Calif., January 13, 2020 — Calithera Biosciences, Inc. , a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, provided today an overview of select expected fourth quarter 2019 financial results, initial 2020 financial guidance and upcoming corporate milestones. “We anticipate that 2020 will be an exciting year for Calithera, building on the substantial progress we made in 2019 and the potential for several significant clinical and regulatory milestones,” said Susan Molineaux, PhD, president and chief executive officer of Calithera. “We remain in a strong financial ..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy